Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Madhur Garg, MD, MBA, FACR

Advertisement
Madhur Garg, MD, MBA, FACR

Madhur Garg, MD, MBA, FACR, of Montefiore Einstein

Articles by Madhur Garg, MD, MBA, FACR

Madhur K. Garg, MD, MBA, MBBS

Dr Garg on the Evolution of Proton Therapy in Head and Neck Cancer

ByMadhur Garg, MD, MBA, FACR
August 12th 2026

Madhur K. Garg, MD, MBA, MBBS, discusses the use of proton therapy in head and neck cancer.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

    2

    CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease

    3

    FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test

    4

    T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer

    5

    Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us